CLX

Business Profile & Competitive Position

The Clorox Company is a Consumer Defensive stock in the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, with fiscal 2026 net sales of $6.7 billion, roughly 9,200 employees, operations in approximately 25 countries and sales in about 95 markets. Its consumer-facing brand list reads like a pantry and cleaning-supply aisle roll call: Clorox bleach and disinfecting products, Pine-Sol, Glad bags and wraps, Fresh Step cat litter, Kingsford charcoal, Hidden Valley dressings, Brita water filtration, and Burt's Bees personal care. On the professional side, Clorox sells Purell, CloroxPro, and Clorox Healthcare products.

In April 2026, Clorox completed the acquisition of GOJO Industries, adding the Purell hand-hygiene platform and expanding its health and hygiene footprint, particularly in business-to-business channels. Scale matters in household staples because shelf space, distribution relationships, and advertising efficiency tend to favor incumbents, and Clorox's portfolio gives it exposure across cleaning, food, pet care, and personal care categories.

The numbers tell a more nuanced story about competitive strength than brand recognition alone. The company reports a net margin of 8.7%, which shows it converts sales into profit, though it is not at the top of the consumer-staples range. The reported return on equity of -1,893.5% is an extreme figure that does not imply operations destroyed nearly nineteen times the company's book value. Instead, it reflects a ratio distortion caused by a very small or negative shareholders' equity denominator, something that can happen after share buybacks, accumulated losses, or accounting adjustments. Because of that, ROE is not a clean measure of Clorox's current operating moat here; investors would normally look at gross margin trends, free cash flow, and category share alongside this distorted equity-based metric. The beta of 0.54 confirms the stock has historically moved roughly half as much as the broad market, consistent with a defensive staples business.

Financial Posture

Clorox currently carries a market capitalization of $12.8 billion and trades at a trailing price-to-earnings ratio of 22.0. For a consumer staples business, that P/E sits in the middle of the pack: not a deep value multiple, but not a steep growth premium either. The net margin of 8.7% supports the idea of a stable, cash-generative company, even if it is not the highest-margin name in the sector.

The most striking number in the financial posture is the -1,893.5% ROE. As noted above, this is not a reflection of recent operating performance in any normal sense; it is a mechanical artifact of the equity base. When ROE is that deeply negative, analysts typically set it aside and look at return on invested capital, operating cash flow, and debt-adjusted valuation metrics. The low 0.54 beta reinforces that Clorox behaves like a defensive holding in market terms, but the balance sheet structure deserves closer inspection before drawing conclusions about shareholder returns.

Strategic Priorities & Outlook

Clorox's most recent 10-K filing outlines a company in transition. Management is executing the IGNITE strategy built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio.

Near-term operational priorities include completing and optimizing a new enterprise resource planning (ERP) system and a broader digital transformation. The goal is to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building. Clorox is also investing in strong brands, strategic digital capabilities, and a streamlined operating model, hoping to build a more resilient company and deliver consistent, profitable growth.

The April 2026 GOJO acquisition is central to the health and hygiene expansion. Management wants to integrate GOJO, grow in professional and institutional markets, and optimize the portfolio around health and hygiene. That portfolio optimization received another jolt on January 31, 2026, when the Glad bags and wraps venture with Procter & Gamble expired. Clorox purchased P&G's 20% interest in the venture, while Glad retained core intellectual property licenses on a royalty-free basis.

The 10-K also flags real risks. Fiscal year 2026 saw declines in organic sales and earnings, with diluted EPS down 26%. Management partly attributed the weakness to macroeconomic headwinds and the timing of the ERP transition, which had pulled some sales forward into fiscal 2025. Customer concentration is another pressure point: Walmart accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half of consolidated net sales.

Macro & Geopolitical Exposure

Because Clorox sits in Consumer Defensive / Household & Personal Products, its exposures are those of a global staples manufacturer rather than a cyclical industrial or technology company. The business is sensitive to commodity inputs such as petrochemicals, resins, paper and packaging, agricultural commodities for food and personal-care products, and energy and freight costs. When those inputs rise, margins compress unless the company can pass higher costs through to retailers and consumers.

Regulation is another standard exposure for this industry. Disinfectant and cleaning products face Environmental Protection Agency oversight, while health and personal-care items can fall under Food and Drug Administration or equivalent foreign agency rules. Changes in labeling, chemical approvals, or sustainability mandates can affect formulation costs and time-to-market. Currency risk matters too, given operations in roughly 25 countries and sales in about 95 markets. A stronger U.S. dollar can compress translated overseas revenue and earnings.

Trade policy and tariffs also sit in the background for household products, particularly when packaging, raw materials, or finished goods move across borders. Perhaps the most immediate macro pressure is consumer behavior: even staple categories see trading down to private-label alternatives during inflationary periods, which directly affects volume growth and pricing power.

Recent Developments

The most recent news cluster is built around Clorox's August 2026 quarterly report. On August 4, 2026, Zacks reported that Clorox's Q4 earnings and sales topped estimates, with GOJO contributing to sales growth. The same day, Zacks noted that management flagged inflation on the earnings call even as share recovery appeared to build. Also on August 4, 2026, Benzinga reported that several analysts raised their forecasts on Clorox following the better-than-expected Q4 results. Earlier, on August 6, 2026, Zacks published a head-to-head value comparison between Newell Brands and Clorox, framing CLX within the peer valuation conversation.

The common thread across these headlines is a company beating near-term expectations while still grappling with input-cost inflation and the integration of a major acquisition. The analyst estimate revisions suggest the August quarter changed some minds about the earnings trajectory, but the inflation commentary is a reminder that pricing and cost pressures have not disappeared.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, Clorox has beaten earnings estimates six times, for a beat rate of 75%, with an average earnings surprise of 9.4%. Across those same quarters, the average five-day price move after earnings has been 1.67%, classified as an upward post-earnings drift.

The last four reports show that the average drift masks significant quarter-to-quarter variation. For the quarter reported August 3, 2026, Clorox delivered actual EPS of $1.66 against an estimate of $1.64, a 1.2% beat, and the stock rose 6.52% the next day and 9.61% over the following five sessions. The prior quarter, reported April 30, 2026, was also a beat: actual EPS of $1.64 versus $1.55 estimated, a 5.8% surprise, yet the stock fell 9.67% the next day and 4.49% over five days. On February 3, 2026, Clorox missed estimates with $1.39 actual against $1.43 estimated, a -2.8% surprise, but the stock still rose 2.43% the next day and 5.63% over five days. Finally, the November 3, 2025 report delivered $0.85 actual versus $0.818 estimated, a 3.9% beat, with a 1.17% next-day gain but a -4.08% five-day drift.

That pattern illustrates a familiar lesson for earnings traders: the direction of the beat or miss does not always determine the post-announcement price move. Management guidance, analyst estimate revisions, and forward-looking commentary can outweigh the single-quarter EPS comparison. The next scheduled report is November 3, 2026, after the market close, with a consensus EPS estimate of $1.07.

For readers who want a fuller picture of how sell-side analysts are currently modeling margins, EPS revisions, and price targets around these developments, the institutional verdict page offers a deeper dive into the consensus view.